Bicocca Open Archive

Logo unimib boa
LISSONI, ANDREA ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.218
EU - Europa 3.840
AS - Asia 1.921
SA - Sud America 141
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 7
Totale 15.150
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.044
IT - Italia 703
SG - Singapore 666
CN - Cina 641
RU - Federazione Russa 593
SE - Svezia 504
UA - Ucraina 487
IE - Irlanda 472
DE - Germania 412
HK - Hong Kong 371
GB - Regno Unito 181
CA - Canada 167
FI - Finlandia 132
AT - Austria 125
BR - Brasile 125
VN - Vietnam 79
FR - Francia 74
DK - Danimarca 45
NL - Olanda 42
IN - India 38
TR - Turchia 27
ID - Indonesia 26
BE - Belgio 21
JP - Giappone 18
ES - Italia 10
EU - Europa 9
KR - Corea 9
PL - Polonia 9
IR - Iran 8
AR - Argentina 6
AU - Australia 6
AL - Albania 5
EC - Ecuador 5
MA - Marocco 5
PH - Filippine 5
RO - Romania 5
TW - Taiwan 5
IQ - Iraq 4
MX - Messico 4
PK - Pakistan 4
UZ - Uzbekistan 4
CH - Svizzera 3
IL - Israele 3
KE - Kenya 3
LA - Repubblica Popolare Democratica del Laos 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
GR - Grecia 2
JO - Giordania 2
MK - Macedonia 2
OM - Oman 2
SC - Seychelles 2
TH - Thailandia 2
UY - Uruguay 2
ZA - Sudafrica 2
AZ - Azerbaigian 1
BD - Bangladesh 1
BO - Bolivia 1
CL - Cile 1
CO - Colombia 1
EE - Estonia 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PT - Portogallo 1
Totale 15.150
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.843
Woodbridge 1.187
Fairfield 676
Houston 663
Jacksonville 519
Dublin 439
Singapore 428
Chandler 414
Wilmington 399
Ashburn 364
Hong Kong 359
Dearborn 335
Seattle 297
Frankfurt am Main 270
Cambridge 255
Princeton 218
New York 207
Santa Clara 168
Milan 164
Vienna 117
Altamura 106
Lawrence 104
Nanjing 104
Lachine 91
Shanghai 81
Beijing 74
Fremont 49
Andover 46
Boardman 46
San Diego 43
Moscow 39
Helsinki 38
Nanchang 37
Ottawa 36
Guangzhou 34
Hebei 34
Los Angeles 33
Toronto 29
Jiaxing 28
Rome 27
Shenyang 27
Council Bluffs 25
Jakarta 25
Changsha 23
Huizen 22
London 22
Tianjin 21
Brussels 20
Falls Church 19
Kunming 18
Norwalk 18
Lissone 17
Dallas 16
Pune 16
Chicago 15
Detroit 15
Dong Ket 14
Hangzhou 14
Bologna 13
Mountain View 13
São Paulo 13
Shenzhen 12
Düsseldorf 10
Florence 10
Monza 10
Munich 10
Nuremberg 10
Jinan 9
University Park 9
Auburn Hills 8
Redmond 8
Zhengzhou 8
Edmonton 7
Lanzhou 7
Leawood 7
Desio 6
Kiev 6
Palermo 6
Sacramento 6
San Mateo 6
Secaucus 6
Tokyo 6
Amsterdam 5
Belo Horizonte 5
Cinisello Balsamo 5
Fuzhou 5
Hefei 5
Hounslow 5
Kraków 5
Naples 5
Rio de Janeiro 5
Taipei 5
Taizhou 5
Tappahannock 5
Tirana 5
Torre Del Greco 5
Turin 5
Verona 5
Wallington 5
Ankara 4
Totale 11.043
Salva come PNG Salva come JPEG
Nome #
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 495
Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery 383
Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms 298
Genomic and epigenomic profile of uterine smooth muscle tumors of uncertain malignant potential (Stumps) revealed similarities and differences with leiomyomas and leiomyosarcomas 273
Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential 263
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production 260
Clinical outcome of patients with malignant tumors associated with mature cystic teratomas of the ovary: A retrospective multicenter Italian study 238
From Conventional Radiotracer Tc-99m with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach 224
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 223
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial 218
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 204
Imact of bevacizumab-containing primary treatment on outcome of recurrent ovarian cancer: An Italian study 198
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 193
Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer 189
OC13. 02: Reproducibility of IETA terms in describing endometrial pathology 186
Early and short-term complications after US-guided puncture of gynecologic lesions: evaluation after 1,000 consecutive cases 177
Uterine leiomyosarcoma: analysis of treatment failures and survival 176
Pre-operative morphological and colour Doppler features of borderline ovarian tumours 174
Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors 171
Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial 170
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 166
Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral versus cervical injection 165
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group 162
Synchronous early-stage endometrial and ovarian cancer 160
Prospective multicenter study on the clinical utility of CA 72.4 in post-menopausal patients with pelvic mass 160
Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer: Validity of pathological response as surrogate endpoint of survival 160
Dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in cervical cancer: Efficacy on pathological response 160
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 157
Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells 156
External validation of diagnostic models to estimate the risk of malignancy in adnexal masses 155
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 152
Prospective multicenter study on CA 125 in postmenopausal pelvic masses 152
Role of puncture and aspiration in expectant management of simple ovarian cysts: a randomised study 150
Brachytherapy for isolated vaginal recurrences from endometrial carcinoma 150
Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy 150
Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma 148
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas 145
Endometrial stromal sarcoma: analysis of treatment failures and survival 141
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 140
Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help 140
Safety of transvaginal fine needle puncture of gynecologic masses: a report after 500 consecutive procedures 140
Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma 139
A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer 138
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies 138
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 137
Antiemetic efficacy of granisetron in patients with gynecological malignancies 135
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 135
Optimal treatment of early-stage ovarian cancer 134
Ovarian cancer prediction in adnexal masses using ultrasound based logistic regression models: a temporal and external validation study by the IOTA group 133
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 133
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis 133
Color Doppler ultrasound in the preoperative assessment of adnexal masses 132
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 132
Ultrasound in the follow-up of young patients with malignant ovarian tumors after conservative surgery 131
Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses 131
Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review 130
Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study 129
Ultrasound characteristics of endometrial hyperplasia described using IETA terms 126
Primary carcinoma of the fallopian tube. A retrospective analysis of 47 patients 125
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 124
Endometriomas: Their ultrasound characteristics 121
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer 120
Effectiveness of autologous blood transfusion in patients undergoing radical hysterectomy 119
Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994 119
Imaging in gynecological disease (7): clinical and ultrasound features of Brenner tumors of the ovary 118
Clinically oriented three-step strategy to the assessment of adnexal pathology 116
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes 114
Alpha-fetoprotein in the management of germ cell tumors of the ovary 114
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study 113
The prognostic relevance of histological type in uterine sarcomas: A cooperation task force (CTF) multivariate analysis of 249 cases 113
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma 113
Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study 112
Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells 111
Ifosfamide in the treatment of malignant epithelial ovarian tumors 110
Brain metastases from endometrial carcinoma 110
Second-look laparotomy in the management of fallopian tube carcinoma 108
Tumor volume as risk factor for nodal diffusion in endometrial cancer 106
Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study 105
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients 103
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice 102
Unilocular adnexal cysts with papillary projections but no other solid components: is there a diagnostic method that can reliably classify them as benign or malignant before surgery? 101
A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study 100
Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis 100
Detection of abnormal intrauterine vascularization by color Doppler imaging: A possible additional aid for the follow up of patients with gestational trophoblastic tumors 99
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas 97
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial 95
The paradigm shift in advanced ovarian cancer: Outcomes of extensive primary cytoreductive surgery. A single-center retrospective analysis 92
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel 91
ΔNp63 expression is associated with poor survival in ovarian cancer 89
Neoplasie dell’apparato genitale femminile 88
Surgical resection of solitary brain metastasis from ovarian carcinoma: an analysis of 22 cases 86
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer 86
Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer 85
Fertility-sparing surgery in uterine leiomyosarcoma 83
Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer 83
Comparison of methods for monitoring young women with stage I borderline ovarian tumor after conservative surgery 82
Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy 81
Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial 80
A prospective study of the role of ultrasound in the management of adnexal masses in pregnancy 80
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 79
Totale 14.461
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.869
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.869
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020352 0 0 0 0 0 0 0 0 0 119 187 46
2020/20211.887 124 82 178 186 122 153 192 179 195 208 109 159
2021/20221.185 74 91 81 112 105 94 55 91 56 85 108 233
2022/20231.892 256 577 134 137 182 297 13 90 125 17 31 33
2023/20241.380 38 43 77 73 181 353 264 33 133 39 19 127
2024/20252.568 195 512 192 196 303 144 268 125 329 304 0 0
Totale 15.548